Description of the Business and Liquidity (Details) $ in Thousands, € in Millions				1 Months Ended							3 Months Ended						9 Months Ended
	Jul. 30, 2021 USD ($)	Jul. 30, 2021 EUR (€)	May 11, 2021 USD ($) tranche	Oct. 31, 2022 USD ($)	Sep. 30, 2022 USD ($)	Aug. 31, 2022 USD ($)	Jul. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2020 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2021 USD ($)	Mar. 31, 2021 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Liquidity
Net loss											$ (73,290)	$ 39,433	$ 19,361	$ 19,507	$ 23,823	$ 27,141	$ (14,496)	$ 70,471
Accumulated deficit					$ 396,209						396,209						396,209		$ 410,705
Government cost share amount																	12,300
Proceeds from sale of PRV, net of transaction costs						$ 107,400											107,375
Cash and cash equivalents					168,249						168,249						168,249		$ 122,927
Oaktree Capital Management LP Credit Agreement
Liquidity
Term of loan facility			5 years
Maximum borrowing capacity available under the credit agreement			$ 100,000
Number of tranches | tranche			4
Proceeds from Lines of Credit			$ 15,000					$ 30,000	$ 30,000								75,000
Remaining borrowing capacity					25,000						25,000						25,000
Additional borrowing capacity available, subject to certain milestone events			$ 25,000
Oaktree Capital Management LP Credit Agreement | Funding of the tranche A- 2 term loans until the funding of the tranche B term loans
Liquidity
Minimum liquidity to be maintained					15,000						15,000						15,000
PRV Asset Purchase Agreement
Liquidity
Amount of consideration to be paid by the acquirer to the Company upon closing of the asset purchase transaction							$ 110,000
Sagard Healthcare Partners
Liquidity
Cash and cash equivalents					32,500						$ 32,500						$ 32,500
BARDA Contract
Liquidity
Maximum amount to be awarded under the contract										$ 51,000
Government cost share amount					12,300	11,500
Company cost share amount					$ 5,300	$ 4,900
Contract base period										2 years
Amount of funding to be provided during contract base period										$ 21,000
Amount of additional funding to be provided following successful completion of clinical trial and preclinical studies in base period										31,000
Cost sharing, amount										33,000
Cost sharing, BARDA amount										$ 52,000
Contract period-of-performance										5 years
Collaboration Agreement with Orion
Liquidity
Upfront fee received	$ 29,600	€ 25.0
R&D reimbursement and cash milestone payments to be received | €		€ 97.0
Number of days from receipt of the final report, in which the collaboration agreement may be terminated	90 days	90 days
Percentage of upfront fee which must be refunded in the event of termination		75.00%
Royalty monetization agreement | Sagard Healthcare Partners | Subsequent events
Liquidity
Upfront Fees Received				$ 32,500
Term Loan Tranche B | Oaktree Capital Management LP Credit Agreement
Liquidity
Proceeds from Lines of Credit								$ 30,000